Current Opinion in Pulmonary Medicine
New Pulmonary Therapies for Cystic Fibrosis CME

Disclosures

Release Date: January 18, 2008; Valid for credit through January 18, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

The paradigm for the treatment of cystic fibrosis has shifted to target the underlying defects or early pathophysiology of the disease. The current article summarizes recent advancements in the treatment of cystic fibrosis.

  1. New Pulmonary Therapies for Cystic Fibrosis
    Felix Ratjen, MD, PhD, FRCP(C)

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the current state of gene therapy for cystic fibrosis
  2. Identify the efficacy of transmembrane regulator pharmacotherapy for cystic fibrosis
  3. List other treatments that have been demonstrated to be effective for cystic fibrosis
  4. Describe the usefulness of osmotic therapy for patients with cystic fibrosis
Authors and Disclosures

Felix Ratjen, MD, PhD, FRCP(C)
Disclosure: Felix Ratjen, MD, PhD, FRCP(C), has disclosed no relevant financial relationships.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.